Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus rhamnosus ha-114
- Development stage
- Unknown
- Lead developer
- Lallemand Health Solutions
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus rhamnosus HA-114 is a specific probiotic strain developed by Lallemand Health Solutions, primarily investigated for its role in modulating the gut-brain axis and metabolic health. Clinical studies have demonstrated that supplementation with HA-114 can improve metabolic markers such as insulin sensitivity, HOMA-IR, and lipid profiles (LDL-cholesterol and triglycerides) in overweight individuals undergoing weight loss. Additionally, the strain has shown psychological benefits, including reductions in binge eating tendencies, disinhibition, and food cravings. In the context of neurodegenerative diseases, HA-114 has been evaluated for its potential to improve cognitive function and metabolic disturbances in patients with mild to moderate Alzheimer's disease and has shown promise in preclinical models of Parkinson's disease for improving hippocampal-dependent cognitive deficits.
- Brand names
- L. rhamnosus HA-114
- Other names
- Lactobacillus rhamnosus HA-114L. rhamnosus HA-114
Beyond the preview
Go deeper on lacticaseibacillus rhamnosus ha-114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus rhamnosus ha-114.